These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 11206463)

  • 21. Indium-mediated atom-transfer and reductive radical cyclizations of iodoalkynes: synthesis and biological evaluation of HIV-protease inhibitors.
    Yanada R; Koh Y; Nishimori N; Matsumura A; Obika S; Mitsuya H; Fujii N; Takemoto Y
    J Org Chem; 2004 Apr; 69(7):2417-22. PubMed ID: 15049639
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Viral proteases as targets for chemotherapeutic intervention.
    Hellen CU; Wimmer E
    Curr Opin Biotechnol; 1992 Dec; 3(6):643-9. PubMed ID: 1369416
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The development of cyclic sulfolanes as novel and high-affinity P2 ligands for HIV-1 protease inhibitors.
    Ghosh AK; Lee HY; Thompson WJ; Culberson C; Holloway MK; McKee SP; Munson PM; Duong TT; Smith AM; Darke PL
    J Med Chem; 1994 Apr; 37(8):1177-88. PubMed ID: 8164260
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Design, synthesis and structure-activity study of shorter hexa peptide analogues as HIV-1 protease inhibitors.
    Narendra Babu SN; Rangappa KS
    Bioorg Med Chem; 2008 Jan; 16(2):874-80. PubMed ID: 17981043
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Insight into the structural similarity between HIV protease and secreted aspartic protease-2 and binding mode analysis of HIV-Candida albicans inhibitors.
    Calugi C; Guarna A; Trabocchi A
    J Enzyme Inhib Med Chem; 2013 Oct; 28(5):936-43. PubMed ID: 22803674
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Aspartic proteases in drug discovery.
    Eder J; Hommel U; Cumin F; Martoglio B; Gerhartz B
    Curr Pharm Des; 2007; 13(3):271-85. PubMed ID: 17313361
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Structure of an inhibitor complex of the proteinase from feline immunodeficiency virus.
    Wlodawer A; Gustchina A; Reshetnikova L; Lubkowski J; Zdanov A; Hui KY; Angleton EL; Farmerie WG; Goodenow MM; Bhatt D
    Nat Struct Biol; 1995 Jun; 2(6):480-8. PubMed ID: 7664111
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Design and synthesis of pseudo-symmetric HIV protease inhibitors containing a novel hydroxymethylcarbonyl (HMC)-hydrazide isostere.
    Hidaka K; Kimura T; Hayashi Y; McDaniel KF; Dekhtyar T; Colletti L; Kiso Y
    Bioorg Med Chem Lett; 2003 Jan; 13(1):93-6. PubMed ID: 12467624
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Design of inhibitors against HIV, HTLV-I, and Plasmodium falciparum aspartic proteases.
    Abdel-Rahman HM; Kimura T; Hidaka K; Kiso A; Nezami A; Freire E; Hayashi Y; Kiso Y
    Biol Chem; 2004 Nov; 385(11):1035-9. PubMed ID: 15576323
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New, potent P1/P2-morpholinone-based HIV-protease inhibitors.
    Kazmierski WM; Furfine E; Spaltenstein A; Wright LL
    Bioorg Med Chem Lett; 2006 Oct; 16(19):5226-30. PubMed ID: 16904316
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synthesis, stability, antiviral activity, and protease-bound structures of substrate-mimicking constrained macrocyclic inhibitors of HIV-1 protease.
    Tyndall JD; Reid RC; Tyssen DP; Jardine DK; Todd B; Passmore M; March DR; Pattenden LK; Bergman DA; Alewood D; Hu SH; Alewood PF; Birch CJ; Martin JL; Fairlie DP
    J Med Chem; 2000 Sep; 43(19):3495-504. PubMed ID: 11000004
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative properties of feline immunodeficiency virus (FIV) and human immunodeficiency virus type 1 (HIV-1) proteinases prepared by total chemical synthesis.
    Schnölzer M; Rackwitz HR; Gustchina A; Laco GS; Wlodawer A; Elder JH; Kent SB
    Virology; 1996 Oct; 224(1):268-75. PubMed ID: 8862421
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Design and synthesis of new inhibitors of HIV-1 protease dimerization with conformationally constrained templates.
    Song M; Rajesh S; Hayashi Y; Kiso Y
    Bioorg Med Chem Lett; 2001 Sep; 11(18):2465-8. PubMed ID: 11549448
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Aza-peptide analogs as potent human immunodeficiency virus type-1 protease inhibitors with oral bioavailability.
    Fässler A; Bold G; Capraro HG; Cozens R; Mestan J; Poncioni B; Rösel J; Tintelnot-Blomley M; Lang M
    J Med Chem; 1996 Aug; 39(16):3203-16. PubMed ID: 8759643
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synthesis and biological evaluation of novel small non-peptidic HIV-1 PIs: the benzothiophene ring as an effective moiety.
    Chiummiento L; Funicello M; Lupattelli P; Tramutola F; Berti F; Marino-Merlo F
    Bioorg Med Chem Lett; 2012 Apr; 22(8):2948-50. PubMed ID: 22414613
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Methodology for protein-ligand binding studies: application to a model for drug resistance, the HIV/FIV protease system.
    Dominy BN; Brooks CL
    Proteins; 1999 Aug; 36(3):318-31. PubMed ID: 10409825
    [TBL] [Abstract][Full Text] [Related]  

  • 37. C2-symmetrical tetrahydroxyazepanes as inhibitors of glycosidases and HIV/FIV proteases.
    Qian X; Morís-Varas F; Fitzgerald MC; Wong CH
    Bioorg Med Chem; 1996 Dec; 4(12):2055-69. PubMed ID: 9022971
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Design and synthesis of highly potent HIV protease inhibitors with activity against resistant virus.
    Lu Z; Raghavan S; Bohn J; Charest M; Stahlhut MW; Rutkowski CA; Simcoe AL; Olsen DB; Schleif WA; Carella A; Gabryelski L; Jin L; Lin JH; Emini E; Chapman K; Tata JR
    Bioorg Med Chem Lett; 2003 May; 13(10):1821-4. PubMed ID: 12729673
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A highly convergent and efficient synthesis of a macrocyclic hepatitis C virus protease inhibitor BI 201302.
    Wei X; Shu C; Haddad N; Zeng X; Patel ND; Tan Z; Liu J; Lee H; Shen S; Campbell S; Varsolona RJ; Busacca CA; Hossain A; Yee NK; Senanayake CH
    Org Lett; 2013 Mar; 15(5):1016-9. PubMed ID: 23406520
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Potent human immunodeficiency virus type 1 protease inhibitors that utilize noncoded D-amino acids as P2/P3 ligands.
    Jungheim LN; Shepherd TA; Baxter AJ; Burgess J; Hatch SD; Lubbehusen P; Wiskerchen M; Muesing MA
    J Med Chem; 1996 Jan; 39(1):96-108. PubMed ID: 8568831
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.